Posted on 12/03/2010 in Medical Company Product News Covidien has received regulatory clearance from the Food and Drug Administration (FDA) to use materials produced by the Maria Research Reactor in Poland in creating medical isotopes.
The medical solutions firm will now be able to use molybdenum 99 (Mo 99) produced by the facility to create generators for Technetium 99m, a vital component of nuclear medicine diagnostic and functional studies.
This supply agreement between Covidien and the Maria facility was confirmed last month, with the Mo 99 supplied by the reactor estimated to aid more than one million patients worldwide within six months.
Covidien's president of pharmaceuticals Timothy Wright welcomed the speed of the FDA's approval, stating that the development will be of benefit to patients.
He said: "Their actions are great news for patients who may have been facing longer delays in receiving critical nuclear medicine diagnostic procedures."
The agreement with the Maria Research Reactor has already been hailed by Covidien as an historic move, as it is the first time in several decades that a new reactor has become part of the global supply chain for medical isotopes.Other news stories from 12/03/2010
Read more in the Zenopa News Archive
How this news is generated
|
